ChemoCentryx

ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
BioSpace
ChemoCentryx
Vifor Fresenius Medical Care Renal Pharma
avacopan
ANCA-positive vasculitis
clinical trials
Flag link:
Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data
Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data
Endpoints
pancreatic cancer
ChemoCentryx
CCX872
Flag link:
ChemoCentryx’s (CCXI) CCX168 Receives Orphan Drug Status
ChemoCentryx’s (CCXI) CCX168 Receives Orphan Drug Status
Bidness Etc.
ChemoCentryx
CCX168
orphan drugs
aHUS
Flag link:
Five Small Biotech Stocks Analysts Think Will Triple
Five Small Biotech Stocks Analysts Think Will Triple
Forbes
Arrowhead Research
ChemoCentryx
Ziopharm
TherapeuticsMD
Dynavax
Flag link:
3 Horrendous Health-Care Stocks This Week
3 Horrendous Health-Care Stocks This Week
Motley Fool
Neurocrine Biosciences
ChemoCentryx
GSK
Avanir
Flag link:
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Seeking Alpha
Neurocrine
ChemoCentryx
CCX140
NBI-98854
tardive dyskinesia
diabetic nephropathy
Flag link:
ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
TheStreet.com
ChemoCentryx
diabetic nephropathy
CCX140
Flag link:
The Impact of a Failed Crohn's Disease Trial Study
The Impact of a Failed Crohn's Disease Trial Study
Motley Fool
Crohn's Disease
Vercirnon
ChemoCentryx
GSK
Flag link:
3 Horrendous Health-Care Stocks This Week
3 Horrendous Health-Care Stocks This Week
Motley Fool
ChemoCentryx
Aglos Pharmaceuticals
Prosensa
Flag link:
GSK's Crohn's disease treatment fails in Phase III trial
GSK's Crohn's disease treatment fails in Phase III trial
Reuters
GSK
Crohn's Disease
ChemoCentryx
Vercirnon
Flag link:
The Best- And Worst-Performing Biotech Stocks, June 28 to July 5
The Best- And Worst-Performing Biotech Stocks, June 28 to July 5
Forbes
biotech
ONYX Pharmaceuticals
Celldex
Novavax
Puma Biotechnology
Endocyte
Alnylam
Bluebird Bio
Dyax
Medivation
Clovis Oncology
Achillion
Insmed
Arena Pharmaceuticals
Avanir
Receptos
Synergy Pharmaceuticals
ChemoCentryx
Idenix
MiMedx
Portola Pharmaceuticals
Flag link:
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
Zerenex
Xoma
Vical
Takeda
sovaprevir
Soluble Ferric Pyrophosphate
Rockwell Medical
Orexigen
MM-398
Merrimack Pharmaceuticals
MannKind
Keryx
GTx
GSK
gevokizumab
enobosarm
Coronado Biosciences
Contrave
CNDO-201
clinical trials
ChemoCentryx
CCX140
Biodel
BIOD-123
Amigal
Amicus Therapeutics
Alnylam
ALN-TTR02
Allovectin
Afrezza
Achillion
ACH-3102
Flag link:
5 Healthcare Companies With Insider Buying During November 2012 - Part III
5 Healthcare Companies With Insider Buying During November 2012 - Part III
Seeking Alpha
Corcept Therapeutics
ChemoCentryx
GSK
Valeant Pharmaceuticals
HealthSouth
Flag link:
6 Biotech Stocks That Could Be In For A Short Squeeze
6 Biotech Stocks That Could Be In For A Short Squeeze
Seeking Alpha
Aveo Pharmaceutical
BioTime
ChemoCentryx
Optimer Pharmaceuticals
Clovis Oncology
PDL Biopharma
Flag link:
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Seeking Alpha
Affymax
Alnylam
Arena Pharmaceuticals
Aveo
BioTime
ChemoCentryx
Emergent BioSolutions
Clovis Oncology
Enzon
Forest Labs
Geron
ViroPharma
Targacept
GSK
Pfizer
Santarus
PDL Biopharma
Infinity Pharmaceuticals
Nektar
Flag link:
22 Biopharma Stocks With Breakout Potential in 2012
22 Biopharma Stocks With Breakout Potential in 2012
Seeking Alpha
Ziopharm
Zalicus
EXACT Sciences
Geron
Lexicon Pharmaceuticals
Nektar
Vical
Celgene
Celsion
ChemoCentryx
Clovis Oncology
Eli Lilly
JNJ
Pfizer
Elan
Biomarin
Biogen Idec
Auxilium
Arqule
Anthera
Acadia
Amicus Therapeutics
Vertex Pharmaceuticals
Flag link:
ChemoCentryx refiles IPO plans, looks to raise $69M
ChemoCentryx refiles IPO plans, looks to raise $69M
ChemoCentryx
IPO
fundraising
Flag link:
ChemoCentryx attempts oral autoimmune drug
ChemoCentryx attempts oral autoimmune drug
Fierce Biotech
ChemoCentryx
autoimmune disease
Flag link:
Glaxo Exercises Drug Option
Glaxo Exercises Drug Option
Yahoo/Zacks.com
GSK
licensing
Merck
Bristol-Myers Squibb
ChemoCentryx
Flag link: